Trade name
Dexdor, Dexmedetomidine (Accord), Dexmedetomidine (Ever Pharma), Dexmedetomidine (Medsurge), Dexmedetomidine (Sandoz), Dexmedetomidine (Viatris), Precedex, Precedex Ready to Use
Strength
100 microgram/mL (volume: 2 mL, 4 mL, 10 mL)
Precedex Ready to Use:
4 microgram/mL (volume: 20 mL, 50 mL, 100 mL)
IV administration
Concentrated solutions must be diluted prior to use.
Dilute to 4 microgram/mL and shake gently to mix. Give as an intermittent or continuous infusion. Refer to relevant local guideline.
Infuse loading dose over 10 to 20 minutes followed by a maintenance dose titrated to response. Refer to relevant local guideline.
Maximum concentration: 8 microgram/mL.
Maintenance doses are expressed as microgram/kg/hour.
RCH Standard Concentrations:
All patients: 200 microgram/50 mL (4 microgram/mL)
Fluid restricted: 400 microgram/50 mL (8 microgram/mL)
Other routes of administration
IM: Not recommended.
SC: Not recommended.
Compatible IV fluids
Sodium chloride 0.9% is the preferred diluent.
Glucose 5%
Hartmann’s
Y-site only and dexmedetomidine in sodium chloride 0.9%:
Potassium chloride 20 mmol/L
Additional information
For use in theatre or intensive care settings only.
Use only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist. Continuous cardiac monitoring recommended.
Rapid administration may cause sinus arrest. Dexmedetomidine infusions may cause hypotension and bradycardia.
A loading dose is optional and may be omitted or reduced (e.g. if a patient is already sedated, hepatically impaired or to reduce the risk of adverse effects); refer to local guidelines. Transient hypertension may occur during administration of the loading dose.
Dexmedetomidine may cause reduced lacrimation. Consider lubrication of patients' eyes to avoid corneal dryness.
Discard any unused vial or bottle contents.
Dexmedetomidine (Accord): Protect from light during storage.
Dexmedetomidine (Medsurge): Clear and colourless to yellowish colour.